PL4058474T3 - Kompozycje i sposoby leczenia nowotworów egfr-dodatnich - Google Patents

Kompozycje i sposoby leczenia nowotworów egfr-dodatnich

Info

Publication number
PL4058474T3
PL4058474T3 PL21769291.2T PL21769291T PL4058474T3 PL 4058474 T3 PL4058474 T3 PL 4058474T3 PL 21769291 T PL21769291 T PL 21769291T PL 4058474 T3 PL4058474 T3 PL 4058474T3
Authority
PL
Poland
Prior art keywords
egfr
compositions
treatment
methods
positive cancer
Prior art date
Application number
PL21769291.2T
Other languages
English (en)
Inventor
Julyun OH
Han Xu
Carl Alexander Kamb
Original Assignee
A2 Biotherapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A2 Biotherapeutics, Inc. filed Critical A2 Biotherapeutics, Inc.
Publication of PL4058474T3 publication Critical patent/PL4058474T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL21769291.2T 2020-08-20 2021-08-19 Kompozycje i sposoby leczenia nowotworów egfr-dodatnich PL4058474T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063068249P 2020-08-20 2020-08-20
US202063105639P 2020-10-26 2020-10-26
US202163230632P 2021-08-06 2021-08-06
PCT/US2021/046733 WO2022040444A1 (en) 2020-08-20 2021-08-19 Compositions and methods for treating egfr positive cancers

Publications (1)

Publication Number Publication Date
PL4058474T3 true PL4058474T3 (pl) 2024-09-23

Family

ID=77711489

Family Applications (1)

Application Number Title Priority Date Filing Date
PL21769291.2T PL4058474T3 (pl) 2020-08-20 2021-08-19 Kompozycje i sposoby leczenia nowotworów egfr-dodatnich

Country Status (21)

Country Link
US (2) US11602544B2 (pl)
EP (2) EP4442815A3 (pl)
JP (2) JP7621461B2 (pl)
KR (1) KR20230052289A (pl)
AU (1) AU2021328478A1 (pl)
BR (1) BR112023002668A2 (pl)
CA (1) CA3189510A1 (pl)
DK (1) DK4058474T3 (pl)
ES (1) ES2984902T3 (pl)
FI (1) FI4058474T3 (pl)
HR (1) HRP20240903T1 (pl)
HU (1) HUE067417T2 (pl)
IL (1) IL300629A (pl)
LT (1) LT4058474T (pl)
MX (1) MX2023002104A (pl)
PL (1) PL4058474T3 (pl)
PT (1) PT4058474T (pl)
RS (1) RS65802B1 (pl)
SI (1) SI4058474T1 (pl)
TW (1) TW202214846A (pl)
WO (1) WO2022040444A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2984902T3 (es) 2020-08-20 2024-10-31 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para EGFR
WO2025030141A1 (en) * 2023-08-02 2025-02-06 A2 Biotherapeutics, Inc. Compositions and methods for treating cancers with hla-a*03 loss of expression
WO2025085867A1 (en) * 2023-10-20 2025-04-24 A2 Biotherapeutics, Inc. Compositions and methods for treating blood cancers
WO2025085846A1 (en) * 2023-10-20 2025-04-24 A2 Biotherapeutics, Inc. Engineered interleukins and uses thereof

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
HK1047109A1 (zh) 1999-10-15 2003-02-07 University Of Massachusetts 作为指定基因干预工具的rna干预轨迹基因
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
RU2402569C2 (ru) * 2004-03-19 2010-10-27 Имклоун Элэлси Человеческие антитела к рецептору эпидермального фактора роста
AU2005250408B2 (en) 2004-05-27 2010-09-23 The Trustees Of The University Of Pennsylvania Novel artificial antigen presenting cells and uses therefor
CN104159909A (zh) 2012-02-22 2014-11-19 宾夕法尼亚大学董事会 产生用于癌症治疗的t细胞持续性群体的组合物和方法
MY189533A (en) 2012-05-25 2022-02-16 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US20150183877A1 (en) * 2012-07-18 2015-07-02 Eli Lilly And Company Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
CA2894668A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas systems and methods for altering expression of gene products in eukaryotic cells
CN105209621B (zh) 2012-12-12 2021-05-25 布罗德研究所有限公司 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
CA2904265C (en) 2013-03-15 2023-08-08 Victor D. FEDOROV Compositions and methods for immunotherapy
ES2769574T3 (es) 2013-03-15 2020-06-26 Michael C Milone Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
WO2015017214A1 (en) 2013-07-29 2015-02-05 Bluebird Bio, Inc. Multipartite signaling proteins and uses thereof
EP3071222B1 (en) 2013-11-21 2020-10-21 UCL Business Ltd Cell
RS66199B1 (sr) 2014-02-04 2024-12-31 The United States Of America As Represented By The Secretary Department Of Health And Human Services Metode za proizvodnju autolognih t ćelija koje su korisne za lečenje b ćelijskih maligniteta i drugih karcinoma i njihove kompozicije
KR102228828B1 (ko) * 2014-03-11 2021-03-16 셀렉티스 동종이형 이식에 양립성인 t-세포들을 만들어내는 방법
CA2967222C (en) 2014-11-12 2023-10-31 Rinat Neuroscience Corp. Inhibitory chimeric antigen receptors
EP3233095A2 (en) 2014-12-17 2017-10-25 Cellectis INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016138034A1 (en) 2015-02-24 2016-09-01 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
AU2016231061B2 (en) 2015-03-11 2020-11-26 Cellectis Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients
AU2016243128A1 (en) 2015-03-27 2017-11-02 University Of Southern California HLA-G as a novel target for CAR T-cell immunotherapy
GB201509413D0 (en) 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
MA44314A (fr) 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
US20210206826A1 (en) 2015-11-19 2021-07-08 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
KR20250134209A (ko) 2015-11-23 2025-09-09 트르스티스 오브 보스톤 유니버시티 키메라 항원 수용체에 관한 방법 및 조성물
EP3383893A4 (en) 2015-12-02 2019-06-26 Innovative Targeting Solutions Inc. T CELL RECEPTORS WITH VARIABLE SINGLE DOMAIN
EP3426690A4 (en) 2016-03-11 2019-10-09 Bluebird Bio, Inc. GENOMEDITIZED IMMUNEFFECTOR CELLS
AU2017286835B2 (en) 2016-06-29 2023-12-14 Crispr Therapeutics Ag Compositions and methods for gene editing
EP3263595A1 (en) 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
CA3038475A1 (en) 2016-09-28 2018-04-05 Immpact-Bio Ltd. A universal platform for car therapy targeting a novel antigenic signature of cancer
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
US20190359678A1 (en) 2017-02-09 2019-11-28 The Regents Of The University Of California Chimeric t cell antigen receptors and methods of use thereof
GB201707779D0 (en) 2017-05-15 2017-06-28 Autolus Ltd Cell
JP7132249B2 (ja) 2017-05-15 2022-09-06 オートラス リミテッド キメラ抗原受容体（ｃａｒ）を含む細胞
GB201707783D0 (en) 2017-05-15 2017-06-28 Autolus Ltd Cell
JP7281774B2 (ja) 2017-09-19 2023-05-26 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア 抗ｈｌａ－ａ２抗体及びその使用方法
US11660315B2 (en) 2017-09-28 2023-05-30 Immpact-Bio Ltd. Universal platform for preparing an inhibitory chimeric antigen receptor (iCAR)
WO2019090215A2 (en) 2017-11-06 2019-05-09 Monticello Daniel J Dominant negative ligand chimeric antigen receptor systems
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
BR112021006100A2 (pt) 2018-09-28 2021-07-20 Immpact-Bio Ltd. métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
EP3632461A1 (en) 2018-10-05 2020-04-08 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
CA3109747A1 (en) 2018-10-05 2020-04-09 St. Anna Kinderkrebsforschung A group of chimeric antigen receptors (cars)
PH12021500051A1 (en) * 2019-06-26 2023-01-23 Amunix Pharmaceuticals Inc Cd3 antigen binding fragments and compositions comprising same
WO2021030153A2 (en) 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
US20240173352A1 (en) * 2019-08-09 2024-05-30 A2 Biotherapeutics, Inc. Cell-surface receptors responsive to loss of heterozygosity
WO2021030182A1 (en) 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Bifunctional single variable domain t cell receptors and uses thereof
US20220289842A1 (en) 2019-08-20 2022-09-15 Senti Biosciences, Inc. Chimeric inhibitory receptor
US20220389075A1 (en) 2019-11-12 2022-12-08 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
WO2021119489A1 (en) 2019-12-11 2021-06-17 A2 Biotherapeutics, Inc. Lilrb1-based chimeric antigen receptor
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
ES2984902T3 (es) 2020-08-20 2024-10-31 A2 Biotherapeutics Inc Composiciones y métodos para tratar cánceres positivos para EGFR

Also Published As

Publication number Publication date
PT4058474T (pt) 2024-07-09
HUE067417T2 (hu) 2024-10-28
JP7621461B2 (ja) 2025-01-24
BR112023002668A2 (pt) 2023-05-02
KR20230052289A (ko) 2023-04-19
LT4058474T (lt) 2024-08-26
RS65802B1 (sr) 2024-08-30
MX2023002104A (es) 2023-07-10
JP2024159820A (ja) 2024-11-08
ES2984902T3 (es) 2024-10-31
EP4058474B1 (en) 2024-05-08
CA3189510A1 (en) 2022-02-24
TW202214846A (zh) 2022-04-16
DK4058474T3 (da) 2024-07-22
JP2023538116A (ja) 2023-09-06
AU2021328478A1 (en) 2023-04-20
IL300629A (en) 2023-04-01
US11602544B2 (en) 2023-03-14
FI4058474T3 (fi) 2024-07-01
SI4058474T1 (sl) 2024-09-30
EP4058474A1 (en) 2022-09-21
US20230277593A1 (en) 2023-09-07
EP4442815A3 (en) 2025-01-01
HRP20240903T1 (hr) 2024-10-11
EP4442815A2 (en) 2024-10-09
US20220273721A1 (en) 2022-09-01
WO2022040444A1 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
PL4058474T3 (pl) Kompozycje i sposoby leczenia nowotworów egfr-dodatnich
EP3953379A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER USING MODIFIED TET2 T LYMPHOCYTE CELL THERAPY
IL288395A (en) Mat2a tricyclic inhibitors and methods for use in cancer therapy
IL300067A (en) Preparations and methods for the treatment of cancers
BR112018070163A2 (pt) compostos de aminopurina substituída, composições e métodos de tratamento
EP4319751A4 (en) THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS
IL308766A (en) Compositions and methods for treating prostate cancer
EP4121077A4 (en) COMPOSITIONS AND METHODS FOR TREATING SOLID AND SOFT TUMORS AND PROLIFERATIVE DISEASES
EP4110822A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
EP4440623A4 (en) Polytherapy for the treatment of cancer
EP4294828A4 (en) COMPOSITIONS AND METHODS FOR THE TREATING HER2-POSITIVE CANCERS
IL309662A (en) Compositions and methods for treating cancers
PL4153232T3 (pl) TERAPIA IMMUNOKONIUGATEM TNF-α DO LECZENIA GUZÓW MÓZGU
IL304467A (en) Pharmaceutical compositions for the treatment of breast cancer and methods of using them
IL315800A (en) Preparations and methods for the treatment of cancer
EP4384220A4 (en) Compositions and methods for treatment of cancer
IL309120A (en) Methods and compositions for the treatment of cancer
EP4370921A4 (en) COMPOSITIONS AND METHODS FOR IMPROVING CANCER TREATMENT
IL287538A (en) Preparations and methods for the treatment of cancer
EP4110923A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF APC-DEFICIENT CANCER
EP4244390A4 (en) COMPOSITIONS AND METHODS FOR IDENTIFYING, EVALUATING AND TREATING A CANCER PATIENT
IL308133A (en) Compositions and methods for treating neuroendocrine tumors
EP3987032A4 (en) Methods and compositions for the treatment of cancer
IL312844A (en) Methods and compositions for treating cancer
IL312846A (en) Methods and preparations for the treatment of cancer